- Report
- November 2024
- 600 Pages
Global
From €3007EUR$3,300USD£2,569GBP
- Report
- February 2025
- 100 Pages
Global
From €5422EUR$5,950USD£4,631GBP
- Report
- December 2024
- 100 Pages
Global
From €5422EUR$5,950USD£4,631GBP
- Report
- March 2025
- 200 Pages
Global
From €4092EUR$4,490USD£3,495GBP
- Report
- November 2024
- 150 Pages
Global
From €4420EUR$4,850USD£3,775GBP
- Drug Pipelines
- September 2024
- 247 Pages
Global
From €7245EUR$7,950USD£6,188GBP
- Report
- April 2025
- 280 Pages
Global
From €2734EUR$3,000USD£2,335GBP
- Report
- March 2022
- 182 Pages
Global
From €2392EUR$2,625USD£2,043GBP
€4784EUR$5,250USD£4,086GBP
- Report
- January 2022
- 224 Pages
Global
From €6334EUR$6,950USD£5,410GBP
- Report
- July 2019
Global
From €911EUR$1,000USD£778GBP
- Report
- October 2023
- 186 Pages
Global
From €4101EUR$4,500USD£3,503GBP
- Report
- June 2023
- 119 Pages
Global
From €4101EUR$4,500USD£3,503GBP
- Report
- September 2021
- 126 Pages
Global
From €13665EUR$14,995USD£11,672GBP
- Report
- August 2022
- 50 Pages
Global
From €1823EUR$2,000USD£1,557GBP
Lutathera is an oncology drug used to treat certain types of neuroendocrine tumors. It is a peptide receptor radionuclide therapy (PRRT) that combines the targeting of a peptide receptor with the therapeutic effect of a radionuclide. The drug is administered intravenously and works by delivering radiation directly to the tumor cells, while sparing healthy tissue.
The Lutathera market is a rapidly growing segment of the oncology drug market. It is expected to experience strong growth in the coming years due to its effectiveness in treating neuroendocrine tumors. The drug is also being studied for its potential to treat other types of cancer, such as prostate and breast cancer.
The Lutathera market is highly competitive, with several major players. These include Novartis, Advanced Accelerator Applications, and Endocyte. Other companies in the market include Ipsen, Merck, and Pfizer. Show Less Read more
